[Skip to Content]
[Skip to Content Landing]
Views 149
Citations 0
Comment & Response
July 3, 2019

Analysis of Pathologic Complete Response 10 Weeks After Radiotherapy—A Radiobiological Sin

Author Affiliations
  • 1Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Oncol. Published online July 3, 2019. doi:10.1001/jamaoncol.2019.1893

To the Editor We read with considerable interest the study by Palma et al.1 The authors included 40 patients with early-stage non–small cell lung cancer (NSCLC), 35 of whom underwent histological examination following resection. The pathological complete response (pCR) rate was 60% at 10 weeks following stereotactic ablative radiotherapy (SABR). The pCR rate was significantly lower than the hypothesized 90% rate. As the first prospective trial (to our knowledge) to evaluate SABR followed by surgery, the study detected the accurate pCR after radiation in patients with NSCLC. In clinical practice, assessment of recurrence after SABR is extremely difficult owing to intense inflammation.